Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease
CRANBURY, N.J. , June 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced today regulatory and clinical advancements in its development program for
View HTML
Toggle Summary Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors
Directors Donald J. Hayden, Jr. and Craig A. Wheeler Re-Elected CRANBURY, N.J. , June 08, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the
View HTML
Toggle Summary Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference
CRANBURY, N.J. , June 01, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics , Inc. (Nasdaq:FOLD) announced today that John F. Crowley , Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming Goldman Sachs 39th Annual Global Healthcare Conference
View HTML
Toggle Summary Amicus Therapeutics Launches Galafold® (Migalastat) for Fabry Disease in Japan
First Oral Precision Medicine for Fabry Patients with an Amenable Mutation Now Available in Japan CRANBURY, N.J. and TOKYO , May 30, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) has initiated the commercial launch of the oral small molecule pharmacological chaperone Galafold ®
View HTML
Toggle Summary Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
CRANBURY, N.J. , May 09, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley , Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV on Tuesday, May 15,
View HTML
Toggle Summary Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates
Continued Global Galafold ® (Migalastat) Adoption and Expansion – Reaffirms FY18 Revenue Guidance of $75M-$85M at Top End of Range Significant Momentum with Pompe Clinical, Regulatory and Manufacturing Activities - GMP Manufacturing Campaigns of ATB200 Drug Substance and Drug Product Completed at
View HTML
Toggle Summary Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018
CRANBURY, N.J. , April 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Tuesday, May 8, 2018 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2018 . The call will be hosted by John F.
View HTML
Toggle Summary Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day
CRANBURY, N.J. , April 17, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) is participating in several activities in April to honor Fabry Disease Awareness Month and International Pompe Day. The Fabry community has designated the month of April to honor and recognize those who living
View HTML
Toggle Summary Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan
First Amicus Medicine and First Oral Precision Medicine for Fabry Patients with an Amenable Mutation in Japan CRANBURY, N.J. , March 22, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the oral small
View HTML
Toggle Summary Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2018
CRANBURY, N.J. , March 05, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced upcoming presentations at two investor conferences in March. John F. Crowley , Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the Cowen & Company 38th
View HTML